期刊文献+

PPAR-γ2基因外显子B的P12A变异与2型糖尿病相关性研究 被引量:2

Relationship between pro12Ala polymorphisms in PPAR-γ2 gene and type 2 diabetes of littoral Han population in Zhejiang Province
下载PDF
导出
摘要 目的研究过氧化物酶体增殖物激活受体-γ2(PPAR—γ2)基因外显子B的P12A变异与2型糖尿病(T2DM)及其相关临床特征。方法选取浙江沿海地区汉族人308例,其中T2DM组126例,对照组182例。对两组对象的基因型采用芯片分型方法进行检测;同时检测两组对象身高、体重、腰围、臀围、空腹血糖(FPG)、餐后2h血糖(2hPG)、血清胰岛素(FINS)及血脂;分析PPAR—γ2基因P12A变异的基因型与各临床变量的关系。结果T2DM组和对照组PPAR—γ2基因中P等位基因和A等位基因的分布频率分别是87.3%、89.6%和12.7%、10.4%,PP基因型频率是74.6%、79.1%,PA+AA基因型频率是25.4%、20.9%,两组基因型及等位基因频率的差异均无统计学意义(均P〉0.05)。T2DM患者PPAR-γ2基因P12A变异携带者与腰围有关(P〈0.05)。结论PPAR—γ2基因P12A多态性在浙江沿海地区主要以PP基因型分布,T2DM组PPAR—γ2基因P12A变异与腰围有关,携带P12A基因者可能影响或加重T2DM脂代谢异常。 Objective To investigate the association of P12A variant in peroxisome proliferators activated receptor-γ2 (PPAR-γ2) gene with type2 diabetes. Methods The genotypes of P12A variants in PPAR-γ2 were determined by gene biochip assay in 308 subjects of littoral Hart population of Zhejiang Province, including 126 patients with type 2 diabetes metlitus, and 182 healthy subjects. The clinical characteristics including height, weight, waist circumference, hip circumference, fast plasma glucose (FPG), 2h plasma glucose after glucose loading (2hPG) and fast insulin (FIN) were measured and their relationship with genotype of P12A variants was analyzed. Results The allele frequencies in the case and control group were 87.3%, 89.6% for P; 12.7%, 10.4% for A respectively. The genotype frequencies were 74.6%, 79.1% for PP; 25.4%, 20.9% for PA+AA. The P12A variant of PPAR-γ2 was not significantly associated with type 2 diabetes (P 〉0.05 ). The frequencies of the Ala 12 carrier in diabetic patients was associated with increased waist circumference(P〈0.05). Conclusion The data show that P12A variant polymorphism of PPAR- γ2 in littoral Han population of Zhejiang is not associated with type 2 diabetes, but it might be a risk factor for metabolic disorder in diabetic patients.
出处 《浙江医学》 CAS 2011年第11期1572-1574,1579,共4页 Zhejiang Medical Journal
基金 温岭市科委资助项目(2008WLCA0046)
关键词 过氧化物酶体增殖物激活受体-γ2基因 2型糖尿病 多态性 Peroxisome proliferators activated receptor-γ2 gene Type 2 diabetes Polymorphism
  • 相关文献

参考文献11

  • 1Hamada T, Kotani K, Tsuzaki K, et al. Association of Prol2 Ala polymorphism in the peroxisome proliferatorfqactivated receptor gammafqgene with small dense Iow density lipoprotein in the general population[J]. Metabolism, 2007, 56(10):1345-1349.
  • 2Helgadottir A, Thorleifsson G, Manolescu A, et al. A common variant on chromosome 9p21 affects the risk of myocardial infarction[J]. Science, 2007, 316:1491-1493.
  • 3艾智华,房殿春,张忠辉.过氧化物酶体增殖体激活受体-γ2基因Pro12Ala多态性与肥胖的关系[J].第三军医大学学报,2008,30(8):691-693. 被引量:7
  • 4刘东霞,华琦,郭金成,刘力松,谭静,刘荣坤,杨峥.过氧化物酶体增生物激活受体γ基因Pro12Ala多态性与高血压的相关性研究[J].首都医科大学学报,2008,29(2):222-226. 被引量:2
  • 5陈雪香,刘合焜.PPARα基因多态性与2型糖尿病关系研究[J].医学综述,2008,14(6):897-899. 被引量:7
  • 6艾智华,房殿春,张忠辉.脂联素基因Gly15Gly多态性与糖尿病大血管病变的关系[J].第三军医大学学报,2008,30(6):536-538. 被引量:11
  • 7Vaccaro O, Lapice E, Montice A, et al. Pro12Ala polymorphism of PPAR gamma 2 locus modulates the relationship between energy intake and body weight in type 2 diabetic patients[J]. Diabetes Care, 2007,30(5):1156-1161.
  • 8Kryukov G V, Sunyaev S R. Most rare missense alleles are deleterious in humans:implications for complex disease and association studies[J]. Am J Hum Genet, 2007,80:727-739.
  • 9Lundholm L, Zang H, Hirschberg A L, et al. Key lipogenic gene expression can be decreased by estrogen in human adipose tissue[J]. Fertil Steril, 2008, 90(1):44-48.
  • 10Balcerzyk A, Zak I, Krauze J. Synergistics effect between polymorphisms of PPAR and ABC1 gene on the premature corenary artery disease[J]. Acta Cardiol, 2007,62(3):233-238.

二级参考文献46

  • 1张颖,雷红,邓幼平.2型糖尿病患者PPARα基因多态性的研究[J].武汉大学学报(医学版),2004,25(4):459-461. 被引量:4
  • 2沈丹,哈黛文.过氧化物酶体增殖物激活受体γ_2基因Pro12Ala变异与冠心病及血脂的关系[J].武汉大学学报(医学版),2005,26(2):253-256. 被引量:3
  • 3张萍,苏本利,于军,王彦,王颖,孙崴,张霞,吕申.过氧化物酶体增殖物激活受体α基因L162V变异与血脂异常的关系[J].中华内分泌代谢杂志,2005,21(2):148-149. 被引量:1
  • 4张爱萍,张木勋,张建华,谢君辉,余毅恺.过氧化物酶体增殖物激活受体γ2基因Pro-12Ala多态性与代谢综合征的相关性研究[J].临床内科杂志,2005,22(10):694-696. 被引量:5
  • 5Takahashi M, Arita Y, Yamagata K, et al. Genomic structure and mutations in adipose-specific gene, adiponectin [ J ]. Int J Obes Relat Metab Disord, 2000, 24(7) : 861-868.
  • 6Stejskal D, Ruzicka V, Adamovska S, et al. Adiponectin concentrations as a criterion of metabolic control in persons with type 2 diabetes mellitus? [J]. Biomed Papers,2003, 147(2): 167-172.
  • 7Zietz B, Hedarth H, Paul G, et al. Adiponectin represents an independent cardiovascular risk factor predicting serum HDL-cholesterol levels in type 2 diabetes[J]. FBES Lett, 2003, 545 (2-3) : 103-104.
  • 8Matsuda M, Shimomura I, Sata M, et al. Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis[ J]. J Biol Chem, 2002, 277(40): 37487-37491.
  • 9Pollin T I, Tanner K, O' connell J R, et al. Linkage of plasma ediponectin levels to 3q27 explained by association with variation in the APMI gene[J]. Diabetes, 2005, 54(1): 268-274.
  • 10Fumeron F, Aubert R, Siddiq A, et al. Adiponectin gene polymorphisms and adiponectin levels are independently associated with the development of hyperglycemia during a 3-year period: the epidemiologic data on the insulin resistance syndrome prospective study [ J ]. Diabetes, 2004, 53(4) :1150-1157.

共引文献23

同被引文献35

  • 1张英梅,李兰荪,陆松鹤,苏海霞,沈敏,张殿新,王海昌.PPARγC161-T基因多态性与冠脉粥样硬化的相关性[J].心脏杂志,2007,19(4):431-433. 被引量:3
  • 2HUMMASTI S, TONTONOZ P. The peroxisome proliferator- activated receptor N-terminal domain controls isotype-selective gene expression and adipogenesis[J]. Molecular Endocrinology, 2006,20(6) :1261-1275.
  • 3BHATIA V, VISWANATHAN P. Insulin resistance and PPAR insulin sensitizers[J]. Current Opinion In Investigational Drugs, 2006,7(10):891-897.
  • 4KENDALL K M, RUBIN C J, MOHIDEEN P, et al. Im provement of giycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual(alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with mefformin monotherapy[J]. Diabetes Care, 2006,29(5) :1016-1023.
  • 5GLASS C K, OQAWA S. Combinatorial roles of nuclear receptors in inflammation and immunity[J]. Nat Rev Immunol, 2006,6(1) :44-55.
  • 6FUJIKI K, KANO F, SHIOTA K, et al. Expression of the peroxisome proliferator activated receptor gamma gene is repressed by DNA methylation in visceral adipose tissue of mouse models of diabetes[J]. BMC Biology, 2009,7 : 38.
  • 7SHI H, LU Y, DU J, et al. Application of back propagation artificial neural network on genetic variants in adiponeetin,per oxisome proliferator-activated receptor-γ, and retinoid X receptor-α genes and type 2 diabetes risk in a Chinese Han population[J]. Diabetes Technol Ther, 2012,14(3): 293-300.
  • 8VALVERDE A M, BENITO M, LORENZO M. The brown adipose sell: a model for understanding the molecular mechanisms of insulin resistance[J]. Aeta Physiol Scand, 2005,183 (1) : 59-73.
  • 9FESTUCCIA W T, BLANCHARD P G, TURCOTTE V, et al. Depot-specifieeffects of the PPARgamma agonist rosiglita- zone on adipose tissue Lipid Res, 2009,50(6).
  • 10XU C, WANG L L, LIU H Y, et al. A novel dual peroxisome proliferator-aetivated receptors alpha and gamma agonist with beneficial effects on insulin resistance and lipid metabolism[J]. Bioteehnology Letters, 2006,28 (12):863-868.

引证文献2

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部